10-Q: The Greater Cannabis Company Reports Q1 2025 Results: No Revenue, Increased Net Loss

The Greater Cannabis Company reported no revenue and an increased net loss for the quarter ended March 31, 2025, while continuing to focus on cannabinoid therapeutic development.

Summary

• The Greater Cannabis Company reported its financial results for the first quarter of 2025.
• The company had no revenue for the three months ended March 31, 2025, and 2024.
• Operating expenses increased to $43,536 in Q1 2025 from $38,951 in Q1 2024, driven by officers' compensation, amortization, professional fees, and R&D costs.
• The net loss for the quarter ended March 31, 2025, was $103,511, compared to a net loss of $44,611 for the same period in 2024.
• The company's cash position was $46,213 as of March 31, 2025, down from $57,368 at the end of 2024.
• The company had $111,357 in outstanding notes payable to third parties as of March 31, 2025.
• The company is focused on developing a novel cannabinoid therapeutic for neuropsychiatric disorders and is awaiting the sourcing of specialized active pharmaceutical ingredients (API) to proceed with a Phase II Clinical Trial.
• The company has concluded there is substantial doubt about its ability to continue as a going concern through March 2026.

Sentiment

Score: 3

Explanation: The company's financial performance is poor, with no revenue, increasing losses, and a low cash position. There is substantial doubt about the company's ability to continue as a going concern. However, the company is pursuing a potentially valuable therapeutic development program.

Positives

• The company has completed preclinical studies for its cannabinoid therapeutic.
• The company has received approval from the Israel Ministry of Health to proceed with a Phase II Clinical Trial.
• The company is focused on developing a novel cannabinoid therapeutic for neuropsychiatric disorders.

Negatives

• The company has no revenue.
• The company's net loss increased significantly.
• The company's cash reserves are low.
• The company is dependent on raising additional funds to finance the Phase II Clinical Trial.
• There is substantial doubt about the company's ability to continue as a going concern.

Risks

• The company may not be able to remediate identified material weaknesses in internal control over financial reporting.
• The company may fail to meet the requirements of agreements under which it acquired business interests.
• The company may be unable to secure additional financing in the near future.
• The company may not be able to attract, retain, and motivate qualified personnel.
• The company faces risks and uncertainties relating to the various industries and operations it is engaged in.
• The company's profitability is uncertain based on its history of losses.
• The company faces risks related to environmental regulation and liability and tax assessments.

Future Outlook

The company plans to conduct clinical studies on and commercialize the cannabinoid-based therapeutic and concentrate on cannabis-related investment and development opportunities.

Industry Context

The company operates in the cannabis industry, which is subject to evolving regulations and market dynamics. The company is focusing on the development of cannabinoid therapeutics, which is a growing area within the industry.

Comparison to Industry Standards

• It is difficult to compare The Greater Cannabis Company to industry standards due to its lack of revenue and focus on early-stage therapeutic development.
• Many cannabis companies are focused on cultivation, processing, and retail sales, while The Greater Cannabis Company is pursuing a biopharmaceutical approach.
• Comparisons could be made to other early-stage biotech companies developing cannabinoid-based therapies, but specific benchmarks would depend on the therapeutic area and stage of development.

Related Party Transactions

• Loans payable to related parties consist of loans from Elisha Kalfa and Yonah Kalfa, and Fernando Bisker and Sigalush, LLC.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial condition and going concern uncertainty.
• Employees face uncertainty due to the company's financial condition and potential curtailment of operations.
• The company's ability to develop and commercialize its therapeutic may impact patients with neuropsychiatric disorders.

Next Steps

• The company needs to source the specialized API required to facilitate the Phase II Clinical Trial.
• The company needs to raise additional funds to finance the cost of the Phase II Clinical Trial.
• The company plans to conduct clinical studies on and commercialize the cannabinoid-based therapeutic.
• The company will concentrate on cannabis-related investment and development opportunities.

Key Dates

Keywords

cannabis, cannabinoid therapeutics, clinical trial, financial results, going concern, net loss, revenue, liquidity, financing, API, biopharmaceutical